COM902 + COM701 + pembrolizumab

This is a **combination immunotherapy regimen** consisting of three monoclonal antibodies: COM701 (an anti-PVRIG immune checkpoint inhibitor), COM902 (an anti-TIGIT immune checkpoint inhibitor), and pembrolizumab (an anti-PD-1 antibody). It achieves triple blockade of the DNAM-1 axis (PVRIG, TIGIT, and PD-1) to activate T cells and natural killer cells, aiming to enhance antitumor immune responses in patients with solid tumors, particularly those refractory to standard treatments. COM901 and COM902 are proprietary candidates developed by Compugen, while pembrolizumab is marketed by Merck. The regimen is in clinical trials for platinum-resistant ovarian cancer and metastatic microsatellite stable colorectal cancer, including patients with liver metastases, with encouraging preliminary safety and antitumor activity[1][2][3][4][5][6][7].

Other names

COM902 + COM701 + pembrolizumabtriple DNAM-1 axis blockadeanti-PVRIG + anti-TIGIT + anti-PD-1 combination